← 返回前沿论文

上尿路尿路上皮癌肿瘤免疫微环境的免疫学特征可预测复发模式

英文原题:Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.

查看英文原题

Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.

PubMed 2026/01/27(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

研究概要

我们的研究表明,UTUC患者TiME中的CD4+ T细胞和Tregs与高病理分期一起,是高危复发的独立预测因素。手术标本中TiME的分析可能为UTUC辅助治疗的疗效提供客观指标。

研究思路结论见上方概要

上尿路尿路上皮癌(UTUC)中肿瘤免疫微环境(TiME)与预后的关联尚不明确。我们研究了TiME与UTUC复发模式之间的关系。

我们评估了90例因UTUC接受肾输尿管切除术的患者,并将其分为无复发组、远处转移组和仅膀胱内复发组。我们使用手术组织通过多重荧光免疫组化评估了TiME与临床病理因素的关联以及三组的预后。

中位年龄为71岁(44-89),其中58例(64%)为男性。非复发组的瘤内CD4 + T细胞密度显著高于其他组(p = 0.0004),而远处转移组的瘤内和瘤周调节性T细胞(Treg;CD3 + CD4 + FoxP3 + 细胞)密度高于仅膀胱内复发组(p = 0.0025)。在多变量分析中,病理T分期和CD4 + T细胞,以及病理T分期和Treg,分别是无复发生存期(p = 0.045,p = 0.017)和无转移生存期(p = 0.027,p = 0.011)的独立预测因子。

展开英文摘要原文

BACKGROUND: The association between the tumor immune microenvironment (TiME) in upper tract urothelial carcinoma (UTUC) and its prognosis remains unclear. We investigated the relationship between TiME and UTUC recurrence patterns. METHODS: We evaluated 90 patients who underwent nephroureterectomy for UTUC and divided them into nonrecurrence, distant metastasis, and intravesical recurrence-only groups. We assessed the association of the TiME with clinicopathological factors using surgical tissues and the prognosis of the three groups via multiplex fluorescence immunohistochemistry. RESULTS: The median age was 71 years (44-89), and 58 (64%) were male. Intratumoral CD4 + T cell density was significantly higher in the nonrecurrence group (p = 0.0004) than the other groups, whereas intra- and peritumoral regulatory T cell (Treg; CD3 + CD4 + FoxP3 + cell) density was higher in the distant metastases group than the intravesical recurrence-only group (p = 0.0025). In the multivariate analysis, pathological T stage and CD4 + T cells, and pathological T stage and Treg were independent predictors of recurrence-free survival (p = 0.045, p = 0.017) and metastatic-free survival (p = 0.027, p = 0.011), respectively. CONCLUSIONS: Our study demonstrated that CD4 + T cells and Tregs in the TiME of patients with UTUC were independent predictors of high-risk recurrence together with high pathological stage. The analysis of TiME in surgical specimens may provide an objective indicator of the efficacy of adjuvant therapy in UTUC.

论文信息

作者
Takahashi K、Ikarashi D、Kitano S、Tamura D、Abe M、Ito A、Shiomi E、Maekawa S
第一作者单位
Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.Japan
通讯作者单位
Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp.Japan
期刊
Cancer immunology, immunotherapy : CII2026 Jan 27
原文标识
PubMed 41591483 · DOI 10.1007/s00262-025-04254-2